{
    "nctId": "NCT05412953",
    "briefTitle": "Tonation Breathing Technique Method to Ease Aromatase Inhibitor-induced Joint and/or Muscle Pain",
    "officialTitle": "Tonation Breathing Technique, a Non-Pharmacogenic Method to Ease Aromatase Inhibitor-Induced Musculoskeletal Symptoms - A Pilot Study",
    "overallStatus": "COMPLETED",
    "conditions": "Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Change in aromatase inhibitor induced musculoskeletal pain symptoms",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Females with stage I-III breast cancer taking adjuvant aromatase inhibitor (AI) (either standard dose of anastrozole 1 mg daily or letrozole 2.5 mg daily or exemestane 25 mg daily) for greater than 30 days experiencing AI induced musculoskeletal pain scores of 5 or higher on a Likert scale will be enrolled\n* Subjects should have completed any planned surgery for breast cancer, chemotherapy and radiation therapy at least 30 days prior to enrollment\n* Patients should have an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2\n* Patients should be at least 18 years old with no maximum age limit\n\nExclusion Criteria:\n\n* Patients should not have significant underlying pulmonary disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}